GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (STU:65H) » Definitions » Cyclically Adjusted PS Ratio

HTG Molecular Diagnostics (STU:65H) Cyclically Adjusted PS Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2017. Start your Free Trial

What is HTG Molecular Diagnostics Cyclically Adjusted PS Ratio?

As of today (2024-06-08), HTG Molecular Diagnostics's current share price is €0.242. HTG Molecular Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 was €448.43. HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio for today is 0.00.

The historical rank and industry rank for HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:65H's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.5
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

HTG Molecular Diagnostics's adjusted revenue per share data for the three months ended in Mar. 2023 was €0.436. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €448.43 for the trailing ten years ended in Mar. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


HTG Molecular Diagnostics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HTG Molecular Diagnostics Cyclically Adjusted PS Ratio Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.01

Competitive Comparison of HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio falls into.



HTG Molecular Diagnostics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.242/448.43
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HTG Molecular Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, HTG Molecular Diagnostics's adjusted Revenue per Share data for the three months ended in Mar. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=0.436/127.3478*127.3478
=0.436

Current CPI (Mar. 2023) = 127.3478.

HTG Molecular Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 96.871 0.000
201309 0.000 98.790 0.000
201312 224.000 98.326 290.116
201403 299.000 99.695 381.937
201406 123.000 100.560 155.766
201409 337.500 100.428 427.968
201412 526.500 99.070 676.782
201503 25.568 99.621 32.684
201506 32.045 100.684 40.531
201509 23.711 100.392 30.078
201512 29.368 99.792 37.477
201603 20.447 100.470 25.917
201606 43.256 101.688 54.171
201609 20.872 101.861 26.094
201612 32.905 101.863 41.138
201703 29.136 102.862 36.072
201706 29.019 103.349 35.758
201709 48.813 104.136 59.694
201712 92.764 104.011 113.577
201803 24.620 105.290 29.778
201806 26.608 106.317 31.871
201809 25.525 106.507 30.520
201812 42.723 105.998 51.328
201903 17.830 107.251 21.171
201906 32.258 108.070 38.012
201909 28.207 108.329 33.159
201912 13.375 108.420 15.710
202003 5.610 108.902 6.560
202006 4.775 108.767 5.591
202009 3.754 109.815 4.353
202012 5.091 109.897 5.899
202103 2.396 111.754 2.730
202106 3.090 114.631 3.433
202109 3.455 115.734 3.802
202112 4.041 117.630 4.375
202203 1.609 121.301 1.689
202206 1.539 125.017 1.568
202209 1.372 125.227 1.395
202212 2.194 125.222 2.231
202303 0.436 127.348 0.436

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


HTG Molecular Diagnostics  (STU:65H) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


HTG Molecular Diagnostics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HTG Molecular Diagnostics (STU:65H) Business Description

Traded in Other Exchanges
Address
3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.

HTG Molecular Diagnostics (STU:65H) Headlines

No Headlines